ETHOS DISCOVERY ACTS AS AN INCUBATOR FOR SCIENTIFIC INNOVATIONS ADDRESSING UNMET DIAGNOSTIC AND THERAPEUTIC NEEDS.
We will align our scientific studies with the innovation platforms of a variety of academic and other research institutions.
Utilizing the established scientific model of Comparative Oncology, Ethos Discovery will evaluate novel therapeutic and diagnostic approaches for cancer in pets who have naturally developed cancer, rather than in conventional preclinical models of cancer (i.e., the mouse in which cancer was induced or artificially created).
The value and advantages of studying cancer biology and cancer therapy (i.e. Comparative Oncology) in animals with naturally occurring diseases is well documented and extensively reviewed. This approach was recently endorsed by the Health and Medicine Division (HMD), a division of the National Academies of Sciences, Engineering, and Medicine and previously the Institute of Medicine (IOM).
ONE HUNDRED PERCENT OF THE ORGANIZATION’S TIME IS ALLOCATED TO THE ACHIEVEMENT OF THE ORGANIZATION’S TAX-EXEMPT PURPOSE.
The similarity of disorders in pets and humans is widely recognized. It is likely the innovations we are working on will be useful for human patients in the future. In all cases Ethos Discovery will disclose these advances free of charge, and without restriction, to the public and to groups interested in the commercialization of these findings for use in human medical care.
More information on each of our projects and opportunities to donate is available on our website. Please don’t hesitate to contact us, or reach out to an Ethos Discovery Ambassador for more information about our ongoing projects, project pipeline, and more.